I think we need to temper expectations and not have all expectations on “hints” me included. What we know is these data are being presented for the first time at a major breast cancer conference in Munich Germany, and the scientific community is just now getting a hold of this. We don’t know if there are NDA‘s although we suspect there may be, but that doesn’t mean it’s true and we also don’t know if big Pharma is engaged yet. they may want more data as this is a retrospective study and although we find the five patients that are alive extremely compelling big Pharma might want follow up studies that are run by the company with the company may have a strategy to come up with funding to get this confirmational studies done. We also have the CRC data coming out which I believe might be very similar to what we’ve seen with this poster in Munich. Furthering our case that we are definitely on to something but again big Pharma might want confirmational studies with CRC and the good news is we are already enrolling that study and we should show 700 mg is the optimal dose and they’re most likely will be a monitoring of PDL one activity before enduring treatment with LL and if PDL one increases during LL treatment a PDL one or PD one antagonist most likely will be added on. The guys who are running our studies are extremely smart, and I highly doubt they would overlook these crucial study design components